重组人红细胞生成素治疗肿瘤化疗相关性贫血的临床研究

Clinical Research of Recombinant Human Erythropoietin in Treating the Cancer-related Anemia after Hemotherapy

目的：评价重组人红细胞生成素（Recombinant human erythropoietin injection,rHuEpo）治疗肿瘤化疗相关性贫血的疗效和安全性,以及对生存质量的影响。方法：采用随机分组方式,分为治疗组和对照组,分别于1-3周期化疗后6-24小时开始。治疗组（40例）行rHuEpo治疗,150 U/kg皮下注射每周3次,疗程4-8周;对照组（24例）未用rHuEpo治疗,其他治疗如中药及支持治疗两组均相同。所有64例患者若出现严重贫血则给予输血治疗,以保证化疗顺利进行。观察rHuEpo对患者血红蛋白（Hb）、红细胞容积（Hct）、RBC、KPS评分、体重改善情况的影响以及rHuEpo的毒副反应。结果：与对照组相比,治疗组治疗后Hb水平显著提高,8周有效率70%;2周内网织红细胞计数显著提高;应用无严重副反应发生,生存质量改善。结论：rHuEpo治疗肿瘤化疗相关性贫血的疗效肯定,副反应少,能够改善患者生存质量。

To research the effect of Recombinant human erythropietin（rHuEpo） in treating cancer-related anemia after chemotherapy. Methods： Forty case of treated group were treated with support cares and rHuEpo 150U/kg, （Qod）, lasted for 4-8 weeks. Twenty four case of control group were treated with same support cares, but no rHuEpo observed the influence of the rHuEpo to the Hb, Hct, RBC and to life quantity of the sufferer. Results： The overall response rates of treated and control group were 70% and 24%. respectively, and the increased HB of treated group is more higher than that of control group（P〈0.05）. Conclusion： rHuEpo is effective and safe in treating the cancer-related anemia, rHuEpo has the high safety, little characteristics of vice-reaction, can improve the sufferer＇s existence quantity.